In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 4.38 below Cidara Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 58 other companies have achieved higher Quick Ratio than Cidara Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 160 to 576.

Explain Quick Ratio?
How much Cash & cash equivalents CDTX�s has?
What are CDTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CDTX Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q3	(Sep 30 2024) Q2
Y / Y Current Liabilities Change	116.15 %	-18.48 %	-25.4 %	-26.5 %	24.48 %
Y / Y Cash & cash equivalent Change	229.72 %	210.63 %	479.47 %	430.56 %	161.73 %
Quick Ratio MRQ	4.38	15.8	3.45	3.83	2.87
CDTX's Total Ranking	# 576	# 160	# 674	# 617	# 579
Seq. Current Liabilities Change	196.55 %	-33.79 %	-1.5 %	11.76 %	11.85 %
Seq. Cash & cash equivalent Change	-17.74 %	203.64 %	-11.42 %	49.02 %	-22.5 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 59
Healthcare Sector	# 293
Overall Market	# 576

Quick Ratio Statistics
High	Average	Low
39.86	6.65	0.44
(Jun 30 2015)		(Mar 31 2024)

Financial Statements
Cidara Therapeutics Inc 's Current Liabilities	$ 96 Millions	Visit CDTX's Balance sheet
Cidara Therapeutics Inc 's Cash & cash equivalent	$ 420 Millions	Visit CDTX's Balance sheet
Source of CDTX's Sales		Visit CDTX's Sales by Geography

Cumulative Cidara Therapeutics Inc 's Quick Ratio

CDTX's Quick Ratio for the trailling 12 Months

CDTX Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	4.47 %	-15.9 %	-8.77 %	16.95 %	69.71 %
Y / Y Cash & cash equivalent TTM Growth	261.4 %	258.46 %	296.43 %	179.24 %	98.3 %
Quick Ratio TTM	5.69	5.69	3.56	2.57	1.64
Total Ranking TTM	# 3693	# 2842	# 2074	# 2989	# 3316
Seq. Current Liabilities TTM Growth	29.43 %	-4.02 %	-8.35 %	-8.24 %	4.19 %
Seq. Cash & cash equivalent TTM Growth	29.38 %	53.28 %	27.25 %	43.2 %	28.33 %

Quick ratio ranking by company, industry and sector >> Back to CDTX Financial Strength Comparisons >> Go to Compare CDTX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the in Current Liabilities in the Q3 2025 to $95.84 millions, cumulative Quick Ratio remained unchanged at 5.69 above the CDTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 155 other companies have achieved higher Quick Ratio than Cidara Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2842 to 3693.

Explain Quick Ratio?
How much Cash & cash equivalents CDTX�s has?
What are CDTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 156
Healthcare Sector	# 953
Within the Market	# 3693

trailing twelve months Quick Ratio Statistics
High	Average	Low
13.97	3.79	0.82
(Dec 31 2016)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Entera Bio Ltd	11.19	$ 8.574 Millions	$ 0.766 Millions
Artiva Biotherapeutics Inc	11.06	$ 122.968 Millions	$ 11.119 Millions
Cullinan Therapeutics Inc	10.54	$ 332.596 Millions	$ 31.569 Millions
Acumen Pharmaceuticals Inc	10.49	$ 126.609 Millions	$ 12.072 Millions
Taysha Gene Therapies Inc	10.39	$ 297.344 Millions	$ 28.631 Millions
Sab Biotherapeutics Inc	10.27	$ 110.881 Millions	$ 10.793 Millions
Pharmacyte Biotech Inc	9.89	$ 15.607 Millions	$ 1.577 Millions
Prokidney Corp	9.68	$ 271.725 Millions	$ 28.072 Millions
Denali Therapeutics Inc	9.41	$ 848.204 Millions	$ 90.146 Millions
Vor Biopharma Inc	9.17	$ 170.462 Millions	$ 18.587 Millions
Leonabio Inc	9.05	$ 25.226 Millions	$ 2.787 Millions
Black Diamond Therapeutics Inc	8.72	$ 135.503 Millions	$ 15.545 Millions
Aura Biosciences Inc	8.60	$ 161.866 Millions	$ 18.823 Millions
Candel Therapeutics Inc	8.29	$ 86.963 Millions	$ 10.492 Millions
Tscan Therapeutics Inc	8.27	$ 184.453 Millions	$ 22.304 Millions
4d Molecular Therapeutics Inc	8.22	$ 305.063 Millions	$ 37.107 Millions
Krystal Biotech Inc	8.01	$ 731.069 Millions	$ 91.268 Millions
Allogene Therapeutics Inc	7.92	$ 252.194 Millions	$ 31.833 Millions
Fate Therapeutics Inc	7.66	$ 215.423 Millions	$ 28.111 Millions
Molecular Partners Ag	7.50	$ 104.149 Millions	$ 13.895 Millions
Solid Biosciences Inc	6.94	$ 236.142 Millions	$ 34.029 Millions
Neumora Therapeutics Inc	6.72	$ 171.525 Millions	$ 25.531 Millions
Repligen Corp	6.70	$ 748.747 Millions	$ 111.822 Millions
Vir Biotechnology Inc	6.65	$ 500.049 Millions	$ 75.222 Millions
Compugen Ltd	6.61	$ 145.640 Millions	$ 22.049 Millions
Scholar Rock Holding Corp	6.53	$ 369.630 Millions	$ 56.647 Millions
Engene Therapeutics Inc	6.47	$ 193.736 Millions	$ 29.965 Millions
Metagenomi Therapeutics Inc	6.22	$ 184.114 Millions	$ 29.583 Millions
Replimune Group Inc	6.12	$ 323.644 Millions	$ 52.900 Millions
Century Therapeutics inc	6.03	$ 132.749 Millions	$ 22.026 Millions

Date modified: 2026-09-08T17:04:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.